Navigation Links
Enterologics Completes Acquisition of BioBalance Corp and Probiotic Product From New York Health Care, Inc
Date:9/8/2011

SAINT PAUL, Minn., Sept. 8, 2011 /PRNewswire/ -- Enterologics, Inc  (ELGO.OB) announced today that it has completed its acquisition of The BioBalance Corporation and its subsidiary BioBalance LLC from New York Health Care, Inc. ("NYHC").  With this purchase Enterologics acquired its first probiotic biotherapeutic product, E. coli M17, or Probactrix®.

E. coli M17 has an active Investigational New Drug application (IND) with the FDA for the indication chronic pouchitis.  Pouchitis is a complication that occurs in patients following surgical treatment of their ulcerative colitis.  This involves removing the colon and reconstructing a rectal pouch, a procedure called restorative proctocolectomy or ilealanal pouch anal anastomosis.  The pouch can become inflamed, accompanied by pain and frequent, sometimes bloody bowel movements, requiring antibiotic treatment.  While the population of pouchitis sufferers is small, the unmet treatment need is significant.  There are at present no FDA-approved drugs for treating this condition, although metronidazole and ciprofloxacin are typically prescribed off-label.  Some patients require continuous antibiotic treatment to maintain remission of their symptoms, which is undesirable due to the side effects of the drugs and the increased likelihood for developing antibiotic-resistant bacteria.  Enterologics will develop E. coli M17 as a maintenance therapy alternative to long-term use of antibiotics and their associated risks. The IND will permit the Company to initiate its first clinical trial, as soon as manufacturing is re-established and adequate financing is in place.

'/>"/>

SOURCE Enterologics, Inc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
2. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
3. Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing
4. Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol
5. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
6. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
7. China Sky One Medical, Inc. Completes Acquisition of Peng Lai Jin Chuang Company
8. Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
9. Roche completes acquisition of ARIUS
10. Water Street Health Care Partners Completes Agreement With Gentiva Health Services to Acquire Majority Ownership of CareCentrix
11. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... Inc. (NYSE: BIOA ) today announced that ... resigned.  The Company has hired Andrew Ashworth , ... 2014, as full time interim CFO and has launched ... Andy Ashworth began his employment today, to overlap ... was the Company,s CFO from September 2011 to December ...
(Date:7/29/2015)... , July 29, 2015  AsureQuality and ... molecular testing for applications in food and primary ... battery powered real-time PCR device, the Freedom4. ... right through to the supermarket shelf for producers, ... includes involvement in animal disease control and pest ...
(Date:7/29/2015)... Research and Markets ... the "Global Biosimilars Market, 2015 - 2025" ... Global Biosimilars Market, 2015 - 2025, report provides ... market. With the blockbuster biologics losing patent protection ... are being viewed as viable substitutes to the ...
(Date:7/29/2015)... July 29, 2015  AmnioChor Inc., an early stage ... very pleased to announce that the Musculoskeletal Transplant Foundation ... to invest in their seed round of development of ... storage capabilities. AmnioChor,s technology allows cryopreservation ... human stem cells living within those tissues. Amnion is ...
Breaking Biology Technology:BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2
... 11 Biomoda, Inc. (OTC,Bulletin Board: BMOD) ( ... M. Gomez has joined Biomoda as a Senior,Research ... its,assay for the early detection of lung cancer., ... associate research scientist at,Lovelace Respiratory Research Institute in ...
... (Nasdaq: BCRX ) today announced Thomas J. ... interim Chief Medical Officer. Dr.,Simon brings more than ... his position at BioCryst., (Logo: http://www.newscom.com/cgi-bin/prnh/20030414/BIOCRYSTLOGO ... have Tom join BioCryst at this important time,",said ...
... Treatments have,commenced on the new Elekta Synergy(R) S ... a world-leading provider of intra- and,extracranial stereotactic radiosurgery., ... 30, 2007 with a colon,cancer treatment followed by ... patients treated with Elekta Synergy S are spine ...
Cached Biology Technology:Biomoda Hires Senior Scientist to Expand Research & Development Effort 2BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities 2BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities 3BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities 4Elekta Announces Clinical Start-up of Elekta Synergy(R) S at UPMC 2Elekta Announces Clinical Start-up of Elekta Synergy(R) S at UPMC 3
(Date:7/9/2015)... , July 9, 2015  Synaptics ... developer of human interface solutions, today announced ... industry,s first fully hardware encapsulated fingerprint sensor ... authentication technology is literally off the grid, ... biometric matching within the fingerprint sensor to ...
(Date:7/8/2015)... SPRINGS, Florida , July 8, 2015 ... constantly evolving as this summer,s must have products such as ... in demand as popularity for biometrics based devices continues to ... are NXT-ID, Inc. (NASDAQ: NXTD ), Google Inc. (NASDAQ: ... Inc. (NYSE: FIT ), GoPro, Inc. (NASDAQ: GPRO ...
(Date:7/2/2015)... 2015 Research and ... the "Natural Language Processing Market by Type ... Pattern & Image Recognition) - Worldwide Forecast to ... The key vendors occupying the market are 3M, ... Corporation, NetBase Solutions, SAS Institute Inc., Verint Systems ...
Breaking Biology News(10 mins):Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2
... first oral, broad-spectrum angiogenesis inhibitor, specially formulated through nanotechnology, ... Children,s Hospital Boston. Findings were published online on June ... Because it is nontoxic and can be taken orally, ... preventive therapy for patients at high risk for cancer ...
... -- Clinician-scientists from NewYork-Presbyterian Hospital/Weill Cornell Medical Center are ... in the care of patients with traumatic brain injury ... be given nutritional supplementation through a gastric feeding tube ... their chances of survival by as much as four-fold. ...
... day, a staggering number of cells perform a feat that ... perfect replicas of each other. The process is called mitosis, ... hallmarks of cancer. Little is known about ... Fox Chase Cancer Center and Technion-Israel Institute of Technology in ...
Cached Biology News:New oral angiogenesis inhibitor offers potential nontoxic therapy for a wide range of cancers 2New oral angiogenesis inhibitor offers potential nontoxic therapy for a wide range of cancers 3Following traumatic brain injury, balanced nutrition saves lives 2Death, division or cancer? Newly discovered checkpoint process holds the line in cell division 2Death, division or cancer? Newly discovered checkpoint process holds the line in cell division 3
cystatin A (N-18)...
Human Cystatin A MAb (Clone 224705)...
...
... Ultra low freezers , Ultima ... critical material storage, Ultima II represents the ... in general purpose and blood bank configurations, ... IntrLogic microprocessor control system with built-in voltage ...
Biology Products: